Topical Application of Imiquimod Gel at Different Concentrations in Actinic Cheilitis

Actinic Cheilitis Clinical Trial

Official title:

Evaluation of Topical Application of 5% Imiquimod, 0.05% Imiquimod and 0.05% Nanoencapsulated Imiquimod Gel in the Treatment of Actinic Cheilitis: a Randomized Controlled Trial

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04219358
• Other study ID #: 2018-0656
• Status: Terminated
• Phase: Phase 1
• Start date: March 23, 2019
• Est. completion date: August 24, 2021

Study information

• Verified date: November 2022
• Source: Hospital de Clinicas de Porto Alegre
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Actinic cheilitis is a potentially malignant lesion on the lower lip, which can progress to more serious illnesses such as cancer if not treated. Usually treatment of this condition is only based on clinical appearance, but there is no established cure treatment. Topical imiquimod is a medicine indicated for the treatment of skin diseases, but it has not yet been proven to treat actinic cheilitis. In this research, the investigator's aim is to evaluate the response to actinic cheilitis treatment with the current standard treatment compared to high and low concentration imiquimod topical formulations.

Description:

Three formulations are used in this research: imiquimod 5%, imiquimod 0.05% e imiquimod nanoencapsulated 0.05%. Nanoencapsulation is a process that concentrates the drug into a capsule not visible to the naked eye, allowing it to penetrate skin more easily and will only release the drug at the lesion site. The drug is presented in a free form inside the gel in the others formulations.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 49
• Est. completion date: August 24, 2021
• Est. primary completion date: June 24, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Individuals with clinical and histopathological diagnosis of actinic cheilitis;
• No previous lip treatment with Imiquimod.

Exclusion Criteria:

• Present lesions suspected of squamous cell carcinoma of the lip.
• Previous history of lip cancer treatment.
• Prior treatment other than standard treatment.
• History of allergic reactions to imiquimod or any other component of the formulas.

Related Conditions & MeSH terms

• Actinic Cheilitis

Intervention

Drug:
• Vehicle Gel Base
Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks. Gel components: medium molecular weight chitosan, lactic acid 85% and water.
• Imiquimod 5% gel
Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks. Gel components: medium molecular weight chitosan, lactic acid 85% and free form imiquimod 5%.
• Imiquimod 0,05% gel
Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks. Gel components: medium molecular weight chitosan, lactic acid 85% and imiquimod 0.05% free form.
• Imiquimod nanoencapsulated 0,05% gel
Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks. Gel components: medium molecular weight chitosan, lactic acid 85% and imiquomod in a nanoencapsulated suspension at concentration of 0,05%
• Lip sunscreen 30 Sun Protector Factor (SPF)
Apply sunscreen on the lip 30 minutes every day before sun exposure. Protects against both UVA (ultraviolet A) and UVB (ultraviolet B rays).
• Dexpanthenol
Apply dexpanthenol on the lip, two (2) times a day, once in the morning and once in the afternoon. Reduces transepidermic water loss and maintaining the natural smoothness and elasticity of the skin. It accelerates the cell renewal, rebuilds damaged tissues and promote the normal keratinisation of the skin and hair.

Locations

Country	Name	City	State
Brazil	Hospital de Clínicas de Porto Alegre	Porto Alegre	Rio Grande Do Sul
Brazil	School of Dentistry - Universidade Federal do Rio Grande do Sul	Porto Alegre	Rio Grande Do Sul

Sponsors (2)

Lead Sponsor	Collaborator
Hospital de Clinicas de Porto Alegre	Federal University of Rio Grande do Sul

Country where clinical trial is conducted

Brazil, 

References & Publications (35)

A Gaspari A, Tyring SK, Rosen T. Beyond a decade of 5% imiquimod topical therapy. J Drugs Dermatol. 2009 May;8(5):467-74. Review. — View Citation

Bernardi A, Braganhol E, Jäger E, Figueiró F, Edelweiss MI, Pohlmann AR, Guterres SS, Battastini AM. Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. Cancer Lett. 2009 Aug 18;281(1):53-63. doi: 10.1016/j.canlet.2009.02.018. Epub 2009 Mar 14. — View Citation

Bernardi A, Frozza RL, Jäger E, Figueiró F, Bavaresco L, Salbego C, Pohlmann AR, Guterres SS, Battastini AM. Selective cytotoxicity of indomethacin and indomethacin ethyl ester-loaded nanocapsules against glioma cell lines: an in vitro study. Eur J Pharmacol. 2008 May 31;586(1-3):24-34. doi: 10.1016/j.ejphar.2008.02.026. Epub 2008 Feb 19. — View Citation

Bernardi A, Zilberstein AC, Jäger E, Campos MM, Morrone FB, Calixto JB, Pohlmann AR, Guterres SS, Battastini AM. Effects of indomethacin-loaded nanocapsules in experimental models of inflammation in rats. Br J Pharmacol. 2009 Oct;158(4):1104-11. doi: 10.1111/j.1476-5381.2009.00244.x. Epub 2009 May 6. — View Citation

Bulcão RP, de Freitas FA, Dallegrave E, Venturini CG, Baierle M, Durgante J, Sauer E, Cassini C, Cerski CT, Zielinsky P, Salvador M, Pohlmann AR, Guterres SS, Garcia SC. In vivo toxicological evaluation of polymeric nanocapsules after intradermal administration. Eur J Pharm Biopharm. 2014 Feb;86(2):167-77. doi: 10.1016/j.ejpb.2013.04.001. Epub 2013 May 2. — View Citation

Bulcão RP, Freitas FA, Venturini CG, Dallegrave E, Durgante J, Göethel G, Cerski CT, Zielinsky P, Pohlmann AR, Guterres SS, Garcia SC. Acute and subchronic toxicity evaluation of poly(e-caprolactone) lipid-core nanocapsules in rats. Toxicol Sci. 2013 Mar;132(1):162-76. doi: 10.1093/toxsci/kfs334. Epub 2012 Dec 12. — View Citation

Cataldo E, Doku HC. Solar cheilitis. J Dermatol Surg Oncol. 1981 Dec;7(12):989-95. — View Citation

Cavalcante AS, Anbinder AL, Carvalho YR. Actinic cheilitis: clinical and histological features. J Oral Maxillofac Surg. 2008 Mar;66(3):498-503. doi: 10.1016/j.joms.2006.09.016. — View Citation

Contri RV, Frank LA, Kaiser M, Pohlmann AR, Guterres SS. The use of nanoencapsulation to decrease human skin irritation caused by capsaicinoids. Int J Nanomedicine. 2014 Feb 12;9:951-62. doi: 10.2147/IJN.S56579. eCollection 2014. — View Citation

Contri RV, Katzer T, Ourique AF, da Silva AL, Beck RC, Pohlmann AR, Guterres SS. Combined effect of polymeric nanocapsules and chitosan hydrogel on the increase of capsaicinoids adhesion to the skin surface. J Biomed Nanotechnol. 2014 May;10(5):820-30. — View Citation

Couvreur P, Barratt G, Fattal E, Legrand P, Vauthier C. Nanocapsule technology: a review. Crit Rev Ther Drug Carrier Syst. 2002;19(2):99-134. Review. — View Citation

Daniel FI, Alves SR, Vieira DS, Biz MT, Daniel IW, Modolo F. Immunohistochemical expression of DNA methyltransferases 1, 3a, and 3b in actinic cheilitis and lip squamous cell carcinomas. J Oral Pathol Med. 2016 Nov;45(10):774-779. doi: 10.1111/jop.12453. Epub 2016 May 9. — View Citation

de Souza Lucena EE, Costa DC, da Silveira EJ, Lima KC. Prevalence and factors associated to actinic cheilitis in beach workers. Oral Dis. 2012 Sep;18(6):575-9. doi: 10.1111/j.1601-0825.2012.01910.x. Epub 2012 Feb 15. — View Citation

dos Santos LR, Cernea CR, Kowalski LP, Carneiro PC, Soto MN, Nishio S, Hojaij FC, Dutra Júnior A, Britto e Silva Filho G, Ferraz AR. Squamous-cell carcinoma of the lower lip: a retrospective study of 58 patients. Sao Paulo Med J. 1996 Mar-Apr;114(2):1117-26. — View Citation

Dufresne RG Jr, Curlin MU. Actinic cheilitis. A treatment review. Dermatol Surg. 1997 Jan;23(1):15-21. Review. — View Citation

Eigentler TK, Kamin A, Weide BM, Breuninger H, Caroli UM, Möhrle M, Radny P, Garbe C. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol. 2007 Oct;57(4):616-21. Epub 2007 Jul 3. — View Citation

Falagas ME, Angelousi AG, Peppas G. Imiquimod for the treatment of actinic keratosis: A meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2006 Sep;55(3):537-8. — View Citation

Ferreira AM, de Souza Lucena EE, de Oliveira TC, da Silveira É, de Oliveira PT, de Lima KC. Prevalence and factors associated with oral potentially malignant disorders in Brazil's rural workers. Oral Dis. 2016 Sep;22(6):536-42. doi: 10.1111/odi.12488. Epub 2016 May 17. — View Citation

Frank LA, Chaves PS, D'Amore CM, Contri RV, Frank AG, Beck RC, Pohlmann AR, Buffon A, Guterres SS. The use of chitosan as cationic coating or gel vehicle for polymeric nanocapsules: Increasing penetration and adhesion of imiquimod in vaginal tissue. Eur J Pharm Biopharm. 2017 May;114:202-212. doi: 10.1016/j.ejpb.2017.01.021. Epub 2017 Feb 1. — View Citation

Frank LA, Sandri G, D'Autilia F, Contri RV, Bonferoni MC, Caramella C, Frank AG, Pohlmann AR, Guterres SS. Chitosan gel containing polymeric nanocapsules: a new formulation for vaginal drug delivery. Int J Nanomedicine. 2014 Jun 28;9:3151-61. doi: 10.2147/IJN.S62599. eCollection 2014. — View Citation

Gebauer K, Shumack S, Cowen PS. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial. Br J Dermatol. 2009 Oct;161(4):897-903. doi: 10.1111/j.1365-2133.2009.09260.x. Epub 2009 May 26. — View Citation

Greenberg HL, Cohen JL, Rosen T, Orengo I. Severe reaction to 5% imiquimod cream with excellent clinical and cosmetic outcomes. J Drugs Dermatol. 2007 Apr;6(4):452-8. — View Citation

Jorizzo J, Dinehart S, Matheson R, Moore JK, Ling M, Fox TL, McRae S, Fielder S, Lee JH. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol. 2007 Aug;57(2):265-8. Epub 2007 May 18. — View Citation

Kaugars GE, Pillion T, Svirsky JA, Page DG, Burns JC, Abbey LM. Actinic cheilitis: a review of 152 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Aug;88(2):181-6. — View Citation

Kopera D, Kerl H. Visualization and treatment of subclinical actinic keratoses with topical imiquimod 5% cream: an observational study. Biomed Res Int. 2014;2014:135916. doi: 10.1155/2014/135916. Epub 2014 May 11. — View Citation

Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007 Dec;157 Suppl 2:34-40. — View Citation

Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J, Lee JH, Fox TL. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004 May;50(5):714-21. — View Citation

Lundeen RC, Langlais RP, Terezhalmy GT. Sunscreen protection for lip mucosa: a review and update. J Am Dent Assoc. 1985 Oct;111(4):617-21. — View Citation

Manganaro AM, Will MJ, Poulos E. Actinic cheilitis: a premalignant condition. Gen Dent. 1997 Sep-Oct;45(5):492-4. — View Citation

McDonald C, Laverick S, Fleming CJ, White SJ. Treatment of actinic cheilitis with imiquimod 5% and a retractor on the lower lip: clinical and histological outcomes in 5 patients. Br J Oral Maxillofac Surg. 2010 Sep;48(6):473-6. doi: 10.1016/j.bjoms.2009.08.024. — View Citation

Poitevin NA, Rodrigues MS, Weigert KL, Macedo CLR, Dos Santos RB. Actinic cheilitis: proposition and reproducibility of a clinical criterion. BDJ Open. 2017 Aug 4;3:17016. doi: 10.1038/bdjopen.2017.16. eCollection 2017. — View Citation

Smith KJ, Germain M, Yeager J, Skelton H. Topical 5% imiquimod for the therapy of actinic cheilitis. J Am Acad Dermatol. 2002 Oct;47(4):497-501. — View Citation

Sotiriou E, Lallas A, Goussi C, Apalla Z, Trigoni A, Chovarda E, Ioannides D. Sequential use of photodynamic therapy and imiquimod 5% cream for the treatment of actinic cheilitis: a 12-month follow-up study. Br J Dermatol. 2011 Oct;165(4):888-92. doi: 10.1111/j.1365-2133.2011.10478.x. Epub 2011 Sep 15. — View Citation

Spyridonos P, Gaitanis G, Tzaphlidou M, Bassukas ID. Spatial fuzzy c-means algorithm with adaptive fuzzy exponent selection for robust vermilion border detection in healthy and diseased lower lips. Comput Methods Programs Biomed. 2014 May;114(3):291-301. doi: 10.1016/j.cmpb.2014.02.017. Epub 2014 Mar 6. — View Citation

Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol. 2010 Apr;62(4):582-90. doi: 10.1016/j.jaad.2009.07.004. Epub 2010 Feb 4. — View Citation

* Note: There are 35 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical Response	Clinical analysis of lip photographs based on a classification. The lesions will be graded as: AC Grade I. Dryness and desquamation on the vermilion of lips.; AC Grade II. Atrophy on the vermilion's border, presenting soft surfaces and pallid areas with eruptions. Blurred limit between the lip's vermilion border and the skin, or a dark line demarking that limit can be seen. This melanotic line should be different from ephelides or other pigmented lesions.; AC Grade III. Rough and squamous areas on the drier parts of the vermilion and hyperkeratotic areas, especially when they spread to the wet lip's mucosa (border between mucosa and semimucosa).; AC Grade IV. Ulceration present in one or more sites of the lip's vermillion or Leukoplakia, mainly in more traumatic places, due to the history of pipe or cigarettes consumption. These lesions could suggest that a malignization process would be in progress, especially when they are accompanied by endured areas on palpation.	30 days after conclusion of treatment
Primary	Clinical Response	Clinical analysis of lip photographs based on a classification. The lesions will be graded as: AC Grade I. Dryness and desquamation on the vermilion of lips.; AC Grade II. Atrophy on the vermilion's border, presenting soft surfaces and pallid areas with eruptions. Blurred limit between the lip's vermilion border and the skin, or a dark line demarking that limit can be seen. This melanotic line should be different from ephelides or other pigmented lesions.; AC Grade III. Rough and squamous areas on the drier parts of the vermilion and hyperkeratotic areas, especially when they spread to the wet lip's mucosa (border between mucosa and semimucosa).; AC Grade IV. Ulceration present in one or more sites of the lip's vermillion or Leukoplakia, mainly in more traumatic places, due to the history of pipe or cigarettes consumption. These lesions could suggest that a malignization process would be in progress, especially when they are accompanied by endured areas on palpation.	180 days after conclusion of treatment
Secondary	General Satisfaction about the medication: Visual Analogue Scale (VAS)	Satisfaction will be self-reported by VAS scale. The visual analogue scale (VAS) will be used to measure general satisfaction of participants to treatment. Participants will be asked to point in to a white paper with a 10cm line, where 0 represents none satisfaction and 10 maximum satisfaction.	VAS scale will be generated at 14 days after beginning of the treatment.
Secondary	General Satisfaction about the medication: Visual Analogue Scale (VAS)	Satisfaction will be self-reported by VAS scale. The visual analogue scale (VAS) will be used to measure general satisfaction of participants to treatment. Participants will be asked to point in to a white paper with a 10cm line, where 0 represents none satisfaction and 10 maximum satisfaction.	VAS scale will be generated at 28 days after beginning of the treatment.
Secondary	General Satisfaction about the medication: Visual Analogue Scale (VAS)	Satisfaction will be self-reported by VAS scale. The visual analogue scale (VAS) will be used to measure general satisfaction of participants to treatment. Participants will be asked to point in to a white paper with a 10cm line, where 0 represents none satisfaction and 10 maximum satisfaction.	VAS scale will be generated at 60 days after beginning of the treatment.
Secondary	General Satisfaction about the medication: Visual Analogue Scale (VAS)	Satisfaction will be self-reported by VAS scale. The visual analogue scale (VAS) will be used to measure general satisfaction of participants to treatment. Participants will be asked to point in to a white paper with a 10cm line, where 0 represents none satisfaction and 10 maximum satisfaction.	VAS scale will be generated at 210 days after beginning of the treatment.
Secondary	Adverse Events Severity	Adverse effects will be assessed during clinical evaluation at follow-up and with an adverse effects questionnaire.The questionnaire is based on self-reported events followed by a quantification of severity of local and systemic events. The participants are asked to classify the events in a scale of 0 to 3. 0= no sympton, 1- mild, 2-moderate and 3-severe.	The adverse events questionnaire is applied in 14 days after beginning of the treatment.
Secondary	Adverse Events Severity	Adverse effects will be assessed during clinical evaluation at follow-up and with an adverse effects questionnaire.The questionnaire is based on self-reported events followed by a quantification of severity of local and systemic events. The participants are asked to classify the events in a scale of 0 to 3. 0= no sympton, 1- mild, 2-moderate and 3-severe.	The adverse events questionnaire is applied in 28 days after beginning of the treatment.
Secondary	Adverse Events Severity	Adverse effects will be assessed during clinical evaluation at follow-up and with an adverse effects questionnaire.The questionnaire is based on self-reported events followed by a quantification of severity of local and systemic events. The participants are asked to classify the events in a scale of 0 to 3. 0= no sympton, 1- mild, 2-moderate and 3-severe.	The adverse events questionnaire is applied in 60 days after beginning of the treatment.
Secondary	Adverse Events Severity	Adverse effects will be assessed during clinical evaluation at follow-up and with an adverse effects questionnaire.The questionnaire is based on self-reported events followed by a quantification of severity of local and systemic events. The participants are asked to classify the events in a scale of 0 to 3. 0= no sympton, 1- mild, 2-moderate and 3-severe.	The adverse events questionnaire is applied in 210 days after beginning of the treatment.
Secondary	Maturation epithelial pattern	Upon confirmation of the diagnosis of actinic cheilitis, participants will undergo a noninvasive procedure called exfoliative cytology. With this examination it is possible to analyze morphological changes of the collected cells by light microscopy. The lip mucosa is scraped with cytobrush, which is then used to smear two glass slides. From one of the obtained smears, Papanicolaou stain will be performed. Papanicoloau staining allows assessing different cell types, which are quantified to evaluate epithelial differentiation.	Maturation epithelial pattern analysis will be performed at 28 days after beginning of the treatment.
Secondary	Maturation epithelial pattern	Upon confirmation of the diagnosis of actinic cheilitis, participants will undergo a noninvasive procedure called exfoliative cytology. With this examination it is possible to analyze morphological changes of the collected cells by light microscopy. The lip mucosa is scraped with cytobrush, which is then used to smear two glass slides. From one of the obtained smears, Papanicolaou stain will be performed. Papanicoloau staining allows assessing different cell types, which are quantified to evaluate epithelial differentiation.	Maturation epithelial pattern analysis will be performed at 60 days after beginning of the treatment.
Secondary	Maturation epithelial pattern	Upon confirmation of the diagnosis of actinic cheilitis, participants will undergo a noninvasive procedure called exfoliative cytology. With this examination it is possible to analyze morphological changes of the collected cells by light microscopy. The lip mucosa is scraped with cytobrush, which is then used to smear two glass slides. From one of the obtained smears, Papanicolaou stain will be performed. Papanicoloau staining allows assessing different cell types, which are quantified to evaluate epithelial differentiation.	Maturation epithelial pattern analysis will be performed at 210 days after beginning of the treatment.
Secondary	Cell proliferation - mAgNOR	Upon confirmation of the diagnosis of actinic cheilitis, participants will undergo a noninvasive procedure called exfoliative cytology. The lip mucosa is scraped with cytobrush, which is then used to smear two glass slides. One slide will be stained with AgNOR. With this examination it is possible to analyze cell proliferation activity. From the quantification of AgNORs, the average AgNORs / core (mAgNOR) will be calculated. The low average of AgNOR stained cells indicates lower cell proliferation and a higher average indicates greater proliferation.	mAgNOR analysis will be performed at 28 days after beginning of the treatment.
Secondary	Cell proliferation - mAgNOR	Upon confirmation of the diagnosis of actinic cheilitis, participants will undergo a noninvasive procedure called exfoliative cytology. The lip mucosa is scraped with cytobrush, which is then used to smear two glass slides. One slide will be stained with AgNOR. With this examination it is possible to analyze cell proliferation activity. From the quantification of AgNORs, the average AgNORs / core (mAgNOR) will be calculated. The low average of AgNOR stained cells indicates lower cell proliferation and a higher average indicates greater proliferation.	mAgNOR analysis will be performed at 60 days after beginning of the treatment.
Secondary	Cell proliferation - mAgNOR	Upon confirmation of the diagnosis of actinic cheilitis, participants will undergo a noninvasive procedure called exfoliative cytology. The lip mucosa is scraped with cytobrush, which is then used to smear two glass slides. One slide will be stained with AgNOR. With this examination it is possible to analyze cell proliferation activity. From the quantification of AgNORs, the average AgNORs / core (mAgNOR) will be calculated. The low average of AgNOR stained cells indicates lower cell proliferation and a higher average indicates greater proliferation.	mAgNOR analysis will be performed at 210 days after beginning of the treatment.
Secondary	Cell proliferation - pAgNOR	Upon confirmation of the diagnosis of actinic cheilitis, participants will undergo a noninvasive procedure called exfoliative cytology. The lip mucosa is scraped with cytobrush, which is then used to smear two glass slides. One slide will be stained with AgNOR. With this examination it is possible to analyze cell proliferation activity. A second evaluation parameter will be the percentage of cells with more than 1, 2, 3 and 4 AgNORs / nucleus (pAgNOR). A higher percentage of cells with more than 3 and 4 AgNORs per nucleus indicate greater proliferation.	pAgNOR analysis will be performed at 28 days after beginning of the treatment.
Secondary	Cell proliferation - pAgNOR	Upon confirmation of the diagnosis of actinic cheilitis, participants will undergo a noninvasive procedure called exfoliative cytology. The lip mucosa is scraped with cytobrush, which is then used to smear two glass slides. One slide will be stained with AgNOR. With this examination it is possible to analyze cell proliferation activity. A second evaluation parameter will be the percentage of cells with more than 1, 2, 3 and 4 AgNORs / nucleus (pAgNOR). A higher percentage of cells with more than 3 and 4 AgNORs per nucleus indicate greater proliferation.	pAgNOR analysis will be performed at 60 days after beginning of the treatment.
Secondary	Cell proliferation - pAgNOR	Upon confirmation of the diagnosis of actinic cheilitis, participants will undergo a noninvasive procedure called exfoliative cytology. The lip mucosa is scraped with cytobrush, which is then used to smear two glass slides. One slide will be stained with AgNOR. With this examination it is possible to analyze cell proliferation activity. A second evaluation parameter will be the percentage of cells with more than 1, 2, 3 and 4 AgNORs / nucleus (pAgNOR). A higher percentage of cells with more than 3 and 4 AgNORs per nucleus indicate greater proliferation.	pAgNOR analysis will be performed at 210 days after beginning of the treatment.